Evidence-Based Therapies for ST-Segment-Elevation Myocardial Infarction Improve Survival

A national registry in Sweden captures comprehensive data on the evolution of STEMI treatment and outcomes.

Several reports have described trends in therapy and outcomes in patients with myocardial infarction (MI), but few have included unrestricted populations. This study focuses on trends in evidence-based therapies and mortality in 61,238 patients who had a first-time diagnosis of ST-segment-elevation MI (STEMI) at acute cardiac care hospitals throughout Sweden from 1996 through 2007.

Over the study period, the mean age of the STEMI patients decreased from 71 to 69; rates of baseline hypertension and cigarette use increased; and the proportions taking statins, angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), or both at admission increased. The rate of fibrinolysis declined from 66% in 1996–1997 to 7% in 20…

Reviewing Author

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)

Frederick A. Masoudi, MD, MSPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardBristol Myers Squibb; CPC Clinical Research

Grant/Research SupportNational Heart, Lung, and Blood Institute

Editorial BoardsUpToDate; American College of Cardiology Self-Assessment Program (SAP)

Leadership Positions in Professional SocietiesAmerican College of Cardiology (Chair, Innovations Committee)